Innovation
into.blood
Developing
therapies.for
the.treatment
of.rare.diseases
Developing and commercializing specialized therapies for the treatment of rare diseases by using the patient’s own blood
Latest News
View allQuince Therapeutics to Acquire EryDel SpA
July 24, 2023
Quince is pleased to announce that it has entered into an agreement to acquire EryDel SpA, a privately-held, late-stage biotech company with an innovative autologous intracellular drug encapsulation (AIDE) technology and a Phase 3 lead asset, EryDex.
EryDex targets a rare fatal pediatric neurological disease, Ataxia-Telangiectasia, which currently has no approved treatments and represents an estimated $1+ billion peak sales opportunity.
Learn more about the EryDel acquisition:
News Release Presentation
Our Technology
EryDel’s proprietary platform technology is an easy to use, fast and automatic bedside procedure, to encapsulate small and large molecules including therapeutic enzymes in patients’ red blood cells. The cells are immediately re-infused into patients providing prolonged half-life in circulation, reduced immunogenicity, better tolerability and predictable vascular distribution.
Discover
